UBS AM’s Syneos Health, Inc. Class A Common Stock SYNH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2023
Q3
Sell
-158,242
Closed -$5.64M 2718
2023
Q2
$5.64M Hold
158,242
﹤0.01% 1176
2023
Q1
$5.64M Buy
158,242
+10,653
+7% +$379K ﹤0.01% 1176
2022
Q4
$5.41M Sell
147,589
-303
-0.2% -$11.1K ﹤0.01% 1142
2022
Q3
$6.97M Sell
147,892
-71,366
-33% -$3.36M ﹤0.01% 1086
2022
Q2
$15.7M Buy
219,258
+1,301
+0.6% +$93.3K 0.01% 796
2022
Q1
$17.6M Buy
217,957
+17,704
+9% +$1.43M 0.01% 873
2021
Q4
$20.6M Buy
200,253
+2,075
+1% +$213K 0.01% 892
2021
Q3
$17.3M Buy
198,178
+984
+0.5% +$86.1K 0.01% 908
2021
Q2
$17.6M Buy
197,194
+84,154
+74% +$7.53M 0.01% 921
2021
Q1
$8.57M Sell
113,040
-4,846
-4% -$368K ﹤0.01% 1132
2020
Q4
$8.03M Buy
117,886
+29,638
+34% +$2.02M ﹤0.01% 1128
2020
Q3
$4.69M Buy
88,248
+10,297
+13% +$547K ﹤0.01% 1176
2020
Q2
$4.54M Buy
77,951
+8,005
+11% +$466K ﹤0.01% 1155
2020
Q1
$2.76M Sell
69,946
-1,323
-2% -$52.2K ﹤0.01% 1286
2019
Q4
$4.24M Sell
71,269
-3,259
-4% -$194K ﹤0.01% 1259
2019
Q3
$3.97M Buy
74,528
+18,335
+33% +$976K ﹤0.01% 1299
2019
Q2
$2.87M Buy
56,193
+7,088
+14% +$362K ﹤0.01% 1415
2019
Q1
$2.54M Buy
49,105
+7,142
+17% +$370K ﹤0.01% 1407
2018
Q4
$1.65M Buy
41,963
+1,745
+4% +$68.7K ﹤0.01% 1518
2018
Q3
$2.07M Buy
40,218
+1,954
+5% +$101K ﹤0.01% 1487
2018
Q2
$1.79M Buy
38,264
+9,290
+32% +$436K ﹤0.01% 1551
2018
Q1
$1.03M Buy
28,974
+1,675
+6% +$59.5K ﹤0.01% 1771
2017
Q4
$1.19M Sell
27,299
-4,476
-14% -$195K ﹤0.01% 1668
2017
Q3
$1.66M Buy
31,775
+2,053
+7% +$107K ﹤0.01% 1478
2017
Q2
$1.74M Sell
29,722
-396
-1% -$23.2K ﹤0.01% 1416
2017
Q1
$1.38M Buy
30,118
+6,423
+27% +$294K ﹤0.01% 1500
2016
Q4
$1.25M Sell
23,695
-6,386
-21% -$336K ﹤0.01% 1471
2016
Q3
$1.34M Buy
30,081
+8,560
+40% +$382K ﹤0.01% 1546
2016
Q2
$821K Buy
21,521
+7,889
+58% +$301K ﹤0.01% 1736
2016
Q1
$562K Sell
13,632
-2,927
-18% -$121K ﹤0.01% 1869
2015
Q4
$803K Hold
16,559
﹤0.01% 1828
2015
Q3
$662K Buy
16,559
+10,759
+186% +$430K ﹤0.01% 1874
2015
Q2
$233K Buy
+5,800
New +$233K ﹤0.01% 2517